reports
- ABGSC IT Research
- Daniel Thorsson
- Simon Granath
- ABGSC IT Research
- Herman Caspersen
- Øystein Elton Lodgaard
- Christoffer Wang Bjørnsen
Nordic Semiconductor (Buy, TP: NOK160.00) - Not too bad given tail-end...
While implied guidance for H1 revenues is ~1–4% below our forecast and consensus, the underlying sequential performance is directionally in line with the broader set of peers to have reported to date. We find this growth and gross margin profile solid, given we are at the tail-end of the life of Nordic’s 10-year-old 55nm technology platform. Combined with the arguably unprecedented level of uncertainty for the company’s customers, we find it achieving a ~50% gross margin and accelerated Cellular...
Nordic Semiconductor ASA: 1 director
A director at Nordic Semiconductor ASA bought 20,090 shares at 102.500NOK and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
- Patrik Ling
Swedish Orphan Biovitrum (Buy, TP: SEK365.00) - Haemophilia the highli...
Q1 sales beat our forecast by 5% and adj. EBITA outperformed by 8%. Overall, we believe the highlight in the report was the stronger haemophilia result than expected, with solid growth in Altuvoct and a smaller decline for Elocta than forecast. The weak spot was Vonjo sales, which missed our estimate by 28% and consensus by 29%, with management citing stocking issues. We reiterate our BUY and SEK365 target price.
- ABGSC IT Research
- Herman Caspersen
- Øystein Elton Lodgaard
- ABGSC IT Research
- Herman Caspersen
- Øystein Elton Lodgaard
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- ABGSC IT Research
- Herman Caspersen
- Øystein Elton Lodgaard
- Johannes Grunselius
Stora Enso (Buy, TP: EUR12.00) - Reassuring Q1
After a series of negative earnings surprises, the Q1 results exceeded our expectations, mainly on progress in the key Consumer Packaging division. In addition, we found it reassuring that management reiterated that the forestry asset sale is ongoing, with completion expected before end-H1. We have made limited forecast changes, and reiterate our BUY and EUR12 target price.
- ABGSC Pulp & Paper Research
- Ali Shemmari
- Henrik Bartnes
- Martin Melbye
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- ABGSC Pulp & Paper Research
- Ali Shemmari
- Martin Melbye
Resolutions at the Annual General Meeting in HMS Networks
Resolutions at the Annual General Meeting in HMS Networks HMS Networks AB (publ) held its Annual General Meeting on April 25, 2025. The Meeting resolved in favour of all matters in accordance with the proposals of the Board of Directors and the Nomination Committee. The main contents of the most important resolutions are described below. ALLOCATION OF EARNINGSThe Annual General Meeting resolved in accordance with the Board’s proposal that no dividend shall be paid to the shareholders for the 2024 financial year, and that the profit for 2024 plus the retained earnings carried forward from t...
Beslut vid årsstämman i HMS Networks
Beslut vid årsstämman i HMS Networks HMS Networks AB (publ) har den 24 april 2025 hållit årsstämma. I samtliga ärenden beslutade stämman i enlighet med styrelsens och valberedningens förslag. I det följande redogörs för de viktigaste beslutens huvudsakliga innehåll. VINSTDISPOSITIONÅrsstämman beslutade i enlighet med styrelsens förslag att någon vinstutdelning inte ska lämnas till aktieägarna för räkenskapsåret 2024 och att årets vinst jämte balanserade vinstmedel ska överföras i ny räkning. FASTSTÄLLANDE AV RESULTAT- OCH BALANSRÄKNING OCH ANSVARSFRIHET Årsstämman beslutade att fastställ...
- Joachim Gunell
HMS Networks (Buy, TP: SEK615.00) - Broad-based beat shows promise
Q1 was better than feared on: 1) an intact demand story, with orders beating Visible Alpha consensus by 8%; 2) an inflection point for earnings momentum, with adj. EPS growth for the first time in six quarters; 3) strong FCF easing balance sheet concerns; and 4) we believe it remains well placed for the next industrial automation upcycle and potential reshoring initiatives. We have raised our 2025e EBIT by 4% and our target price to SEK615 (600), and reiterate our BUY.
- ABGSC IT Research
- Daniel Thorsson
- Simon Granath
- ABGSC IT Research
- Daniel Thorsson
- Simon Granath
Interim report: January – March 2025
Interim report: January – March 2025 First quarter Order intake for the first quarter increased by 97% to SEK 930 m (473). Organically, order intake increased by 12%, acquired growth was 89% and currency effects impacted by -4%Net sales increased by 44% to SEK 890 m (616). Organically, net sales decreased by 17%. Acquired growth was 59% and currency translations impacted by 2%Adjusted EBIT reached SEK 218 m (137), equal to a 24.5% (22.2) adjusted operating marginEBIT reached SEK 175 m (130), equal to a 19.6% (21.1) operating marginAdjusted profit after tax totaled SEK 159 m (113) and adjus...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.